Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

Autor:	de Goër de Herve MG; INSERM 1186, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France., Dekeyser M; INSERM 1186, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France., Hendel-Chavez H; INSERM 1186, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France., Maillart E; Department of Neurology, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France., Labeyrie C; Department of Neurology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France., Adams D; Department of Neurology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France., Moreau T; Department of Neurology, CHU Dijon, Dijon, France., Lubetzki C; Department of Neurology, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France., Papeix C; Department of Neurology, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France., Stankoff B; Department of Neurology, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Paris, France., Gasnault J; INSERM 1186, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.; Unité de Suite et Réadaptation, Department of Internal Medicine, Hôpital de Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France., Taoufik Y; INSERM 1186, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Jul 17; Vol. 15, pp. 1416074. Date of Electronic Publication: 2024 Jul 17 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1416074
Abstrakt:	Introduction: Progressive Multifocal Leukoencephalopathy (PML) is a rare and deadly demyelinating disease caused by JC virus (JCV) replication in the central nervous system. PML occurs exclusively in patients with severe underlying immune deficiencies, including AIDS and hematological malignancies. PML has also emerged as a significant threat to patients on potent new immunosuppressive biologics, including natalizumab in multiple sclerosis. Methods: Here, we developed an IFN-γ release assay (IGRA) that mainly detects JCV-specific effector memory T cells and effectors T cells in the blood. Results: This assay was frequently positive in patients with active PML (with a positive JCV PCR in CSF) of various underlying immunosuppression causes (84% sensitivity). Only 3% of healthy donors had a positive response (97% specificity). The frequency of positivity also increased in multiple sclerosis patients according to the time on natalizumab (up to 36% in patients treated for more than 48 months, who are considered at a higher risk of PML). Discussion: The results show this assay's frequent or increased positivity in patients with PML or an increased risk of PML, respectively. The assay may help to stratify the risk of PML. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 de Goër de Herve, Dekeyser, Hendel-Chavez, Maillart, Labeyrie, Adams, Moreau, Lubetzki, Papeix, Stankoff, Gasnault and Taoufik.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu